Possible mechanisms of action of probiotics in individuals with T1D include the change in inflammatory dysbiosis to normobiosis, the reduction in pro-oxidative, inflammation-related cytokines, the production of the anti-inflammatory short chain fatty acids (SCFAs), and GLP-1, which protects against insulin resistance. The gene discussed is GCG; the disease is type 1 diabetes mellitus.